NVCT רווח למניה בשנים עשר החודשים האחרונים Nuvectis Pharma, Inc

The EPS TTM history demonstrates profitability dynamics, where the current status is -1.86. Nuvectis Pharma, Inc. (NVCT) develops targeted therapies in collaboration with scientific centers. The business model relies on the full outsourcing of production and trials through external contractors. High demand for anti-tumor solutions provides the company with stability regardless of global economic shocks.
Nuvectis Pharma, Inc - פילוחים אנליטיים ומדדי מפתח (NVCT)

TTM net income per share measures the final return of a single security over a year, excluding the impact of share issuances or buybacks to identify the real profitability trend. An analysis of TTM fundamental earnings per share allows for an assessment of the financial stability of Nuvectis Pharma, Inc. (NVCT), whose current results depend on investment income until the commercialization of oncology therapy drugs.